Vilya

Vilya is a computational drug design company based in South San Francisco, California, in the United States. It positions itself at the intersection of artificial intelligence and molecular invention, describing its work as "de novo drug design inspired by nature & AI." Rather than screening large libraries of existing compounds, Vilya generates entirely new macrocycles in silico — molecules that do not exist in nature — and advances them toward orally bioavailable medicines. The company's core thesis is that evolution perfected molecular interactions over billions of years, but only within a limited chemical space. Vilya studies those principles and then computes forward into unexplored chemical space, designing molecules with atomic precision. Its stated mission is to create medicines that do not exist in nature but work within it, combining the targeting precision of antibodies or biologics with the convenience of pills. The company argues that this design-first approach can open doors to previously untreatable diseases, including so-called "undruggable" proteins. Vilya states that it was born from Nobel Prize-winning research at the Institute for Protein Design. Its team brings together people working in computational biology, chemistry, and drug development. The company describes its platform as generating, predicting, and validating entirely new macrocycles in silico, and it is advancing a pipeline of orally bioavailable macrocycles intended to replace some of today's injectable biologics. Publicly described pipeline programs include oncology targets, an integrin α4β7 program for inflammatory bowel disease (IBD), and additional immunology targets. The company also publishes computational research, including an all-atom foundation model called Vilya-2 that is described as accurately modeling chemically diverse molecular interfaces. Vilya operates as a private company. Its public presence centers on its website, vilya.ai, where it presents its platform, pipeline, leadership team, and news. The company's branding emphasizes reverence for nature combined with intentional, principled design — "Inspired by nature. Designed by Vilya."

Vilya is a computational drug design company based in South San Francisco, California, United States. It emerged from what it describes as Nobel Prize-winning research at the Institute for Protein Design, and it has built its identity around the idea of designing entirely new therapeutic molecules rather than discovering existing ones. The company's founding premise is that evolution, over billions of years, perfected molecular interactions but only within a narrow slice of possible chemical space. Vilya studies those natural principles and then uses AI-driven generative methods to compute forward into unexplored chemical space. Its stated mission is to create medicines that do not exist in nature but work within it — molecules designed from first principles with atomic precision. Vilya's platform generates, predicts, and validates entirely new macrocycles in silico. These macrocycles are intended to combine the selectivity of biologics with the convenience of pills, potentially opening doors to previously untreatable diseases. The company is advancing a pipeline of orally bioavailable macrocycles that could replace some of today's injectable biologics. Each molecule is computationally designed to hit its target with precision while crossing biological barriers that stop traditional drugs. Publicly described pipeline programs include oncology targets, an integrin α4β7 program for inflammatory bowel disease (IBD), and additional immunology targets. The company presents its pipeline as progressing through stages such as target selection, hit identification, hit-to-lead, lead optimization, DC selection, and DC-IND. Vilya also invests in foundational computational research. It has published work on an all-atom foundation model called Vilya-2, described as accurately modeling chemically diverse molecular interfaces. The company frames its work as a fundamental shift from discovery to invention: where others screen millions of compounds hoping for hits, Vilya aims to generate molecules purposefully crafted for their targets. Vilya operates as a private company. Its public communications emphasize a culture of principled, de novo design and a team drawn from computational biology, chemistry, and drug development. The company's brand language — "Inspired by nature. Designed by Vilya." — captures its positioning as a company that respectfully extends beyond evolutionary constraints to address human disease.

• Publication of a Vilya research item listed on the company's news page.

• Vilya introduces Vilya-2, an all-atom foundation model that accurately models chemically diverse molecular interfaces.

A computational drug design company creating de novo macrocycles that combine the selectivity of biologics with the convenience of pills, using AI-driven methods to design molecules beyond evolutionary constraints.

• AI-driven macrocycle design platform

  A computational platform that generates, predicts, and validates entirely new macrocycles in silico.

• Oral/permeable drug pipeline

  Orally bioavailable macrocycles designed to hit targets with precision while crossing biological barriers, including oncology and immunology programs.

• Vilya-2

  An all-atom foundation model that accurately models chemically diverse molecular interfaces.

1. 1Vilya | de novo drug design inspired by nature & AIvilya.ai
2. 2Vilya | Aboutvilya.ai
3. 3Vilyawikidata.org